The full reasoning pathway — diagnose menopause clinically, exclude the red flags, weigh individual benefits and risks, and offer HRT for symptom control with the right progestogen for endometrial protection (transdermal preferred); review and safety-net.StartDecisionInvestigateActionReferStop / Admit
PresentationMenopause / HRT
Vasomotor (flushes, sweats), urogenital (dryness, dyspareunia, urinary), mood, sleep, cognitive symptoms; LMP/cycle change. Diagnose clinically — FSH not needed if ≥45 with typical symptoms; check FSH if <45, or 40–45 with symptoms.
Step 1 · Safety — red flags & cautionsAnything to exclude before HRT?
Unscheduled or postmenopausal bleeding → exclude endometrial cancer
Current/past breast cancer (HRT generally contraindicated → specialist)
VTE / high VTE risk or active liver disease → route & regimen caution
Undiagnosed breast lump; uncontrolled hypertension
YES — red flag
Stop · escalate2WW / specialist
PMB → 2WW endometrial pathway. Active/past breast cancer or high VTE risk → specialist advice before HRT (consider non-hormonal options). Breast lump → 2WW breast.
NO — assess & counsel
Step 2 · AssessIndividualise benefit/risk
Discuss benefits vs risks; baseline BP, BMI; personal/family history (breast, VTE). Consider transdermal (lower VTE/stroke risk) and contraception need (HRT is not a contraceptive).
Step 3 · which approach?
Symptom-led / non-hormonal
Individualise
If HRT declined/contraindicated: SSRI/SNRI or others for vasomotor symptoms, CBT, lifestyle; vaginal oestrogen for urogenital symptoms (can be used long-term, even with systemic caution).
HRT regimen (NG23)
Transdermal preferred
Oestrogen + progestogen if uterus (sequential if perimenopausal, continuous combined if postmenopausal); oestrogen-only if no uterus. Transdermal oestrogen avoids first-pass → safer for VTE/stroke; micronised progesterone/dydrogesterone safest.
Premature menopause
POI <40
HRT (or COCP) until the natural age of menopause (~51) for bone & cardiovascular protection — risks not increased vs background.
Step 7 · prescribe & counsel
Step 7 · Action — prescribe with protectionRight oestrogen + right progestogen
Always protect the endometrium — a woman with a uterus on systemic oestrogen needs a progestogen (or LNG-IUS, which also provides contraception).
Menopause specialist complex cases, POI, HRT in women with a personal/family history of hormone-sensitive cancer or thrombosis, or persistent symptoms despite optimisation.
Step 8 · lifestyle & bone/CV health
Step 8 · Lifestyle & long-term healthBeyond symptom control
Weight-bearing exercise, calcium & vitamin D for bone health · cardiovascular-risk reduction (BP, lipids, stop smoking, alcohol) · sleep hygiene, layered clothing and trigger avoidance for flushes · pelvic-floor exercises and vaginal moisturisers/lubricants for urogenital symptoms · CBT for mood/vasomotor symptoms.
Step 9 · review & safety-net
Step 9 · Review & safety-netWhen to come back
Review at 3 months after starting/changing HRT (efficacy, side-effects, BP), then annually. Any unscheduled bleeding on HRT — review and, if persistent/after the settling-in period, refer for endometrial assessment. Reassess breast awareness and screening; report new breast lump, leg swelling/chest symptoms (VTE).
⚠️ Always protect the endometrium: a woman with a uterus on systemic oestrogen needs a progestogen — and any postmenopausal or unscheduled bleeding warrants endometrial assessment. Transdermal oestrogen is the safer route for VTE and stroke risk.
1
Safety
Red Flags — Absolute contraindications & symptoms requiring investigation first
Screen before initiating HRT. Some "menopausal" symptoms are sinister — do not attribute symptoms to menopause without exclusion.
Postmenopausal bleeding (PMB) Any PV bleed >12 months after LMP → 2WW gynaecology before HRT. Must exclude endometrial carcinoma first. HRT will make endometrial pathology worse.
Breast cancer — current or recent HRT absolute contraindication. ALL preparations (including "safer" options). Topical vaginal oestrogen may be permissible — discuss with oncology before prescribing.
Unexplained breast mass or nipple discharge Investigate and refer before HRT initiation. HRT with oestrogen-sensitive malignancy = serious harm. → Urgent breast clinic (2WW)
Current DVT, PE, or arterial thrombosis Oral HRT contraindicated (increases VTE 3-fold). Investigate and treat before deciding on HRT route — transdermal oestrogen does NOT increase VTE risk.
Oestrogen-dependent malignancy (other) Endometrial cancer, ovarian cancer (certain types) — seek specialist advice. Do not initiate HRT without oncology input.
Severe liver disease Active hepatitis, hepatic failure, hepatocellular carcinoma → oral HRT contraindicated (first-pass hepatic metabolism). Transdermal may be possible with specialist guidance.
Atypical / rapidly progressive symptoms Severe unilateral headache, focal neurological symptoms, bone pain, weight loss → investigate before attributing to menopause. May represent malignancy or neurological disease.
Uncontrolled hypertension Check BP before prescribing. Systolic >180 or diastolic >110 → control BP first. Transdermal safer than oral in hypertension (no hepatic renin stimulation).
NICE NG23 (Menopause, 2015 updated 2019) is clear that HRT offers substantial quality-of-life benefits but must not be prescribed without adequate safety screening. The commonest serious error in menopause management is attributing PMB to menopause/HRT side effects and delaying endometrial cancer diagnosis. Breast cancer contraindication applies to all systemic HRT preparations — the MHRA updated advice (2020) confirmed vaginal oestrogen has negligible systemic absorption and may be used with oncology input in most breast cancer patients experiencing genitourinary syndrome.
Menopause is a clinical diagnosis in women >45 years. Investigations rarely needed and often misleading.
Menopause definition
12 months amenorrhoea after last menstrual period (if uterus intact). Average age UK: 51 years. Range: 45–55 years.
Perimenopause
Variable cycle length (≥7 days different from normal), menopausal symptoms, age >40. May still be having periods. Can last 4–8 years before menopause.
Premature menopause (POI)
Menopause <40 years. Requires FSH >40 IU/L on 2 occasions >4 weeks apart to confirm. Refer to specialist — HRT mandatory to age 51 for health reasons (bone, cardiovascular, cognitive).
Early menopause
Age 40–45. Clinical diagnosis + FSH to support. HRT strongly recommended to age 51.
Greene Climacteric Scale or MRS (Menopause Rating Scale) — quantify symptom burden for monitoring response to treatment
Impact on QoL
Work impact, relationship impact, psychological wellbeing. 80% of women have symptoms; 25% describe severe impact. Legitimate medical need — not trivial.
NICE NG23 explicitly states FSH testing is NOT required to diagnose menopause in women over 45 with typical symptoms — FSH fluctuates significantly in perimenopause and a single normal result does not exclude menopause. Testing in under-45s is appropriate to detect premature ovarian insufficiency. POI affects 1% of women under 40 and carries significant long-term health consequences (increased osteoporosis, cardiovascular disease, dementia risk) — early identification and HRT initiation is health-preserving.
3
Diagnose
Risk Assessment — Individualise HRT risks and benefits
HRT risk must be contextualised against absolute risk, not relative risk. Use evidence to guide shared decision-making.
Breast cancer risk
Combined HRT (oestrogen + progestogen): 4 extra cases per 1000 women over 5 years (equivalent to drinking 2 units alcohol/day daily). Oestrogen-only HRT (hysterectomy): no increased risk or slight reduction. Micronised progesterone (Utrogestan) has lowest breast cancer signal vs synthetic progestogens.
VTE risk
Oral oestrogen HRT: doubles VTE risk (absolute: +6 per 10,000 women/year). Transdermal oestrogen: NO increased VTE risk — bypasses hepatic first pass. Use transdermal in all women with VTE risk factors.
Cardiovascular
Starting HRT <60 years or within 10 years of menopause: reduces cardiovascular risk (Window of Opportunity). Starting >60 or >10 years post-menopause: slight increase risk. Timing matters enormously.
Stroke
Oral oestrogen: small increased ischaemic stroke risk (1.5×). Transdermal oestrogen: no increased stroke risk. Use transdermal in women with stroke risk factors.
Endometrial protection
All women with intact uterus MUST have progestogen added to oestrogen. Oestrogen alone → endometrial hyperplasia in 20–40% and cancer risk × 6. IUS (Mirena) is NICE-recommended method of progestogen delivery.
Osteoporosis benefit
HRT reduces hip fracture risk by 27% and vertebral fracture by 37% (WHI data). Protective while taking — benefit does not persist after stopping. Dual benefit for symptomatic menopausal women.
The 2002 Women's Health Initiative (WHI) study caused widespread HRT abandonment based on relative risk data that, in absolute terms, represents very small individual risk increases. Re-analysis showed WHI used predominantly oral conjugated equine oestrogen + medroxyprogesterone — not modern body-identical transdermal oestrogen + micronised progesterone. The British Menopause Society (2020), MHRA (2020), and NICE (2019) all confirm the risk-benefit balance favours HRT use for most symptomatic women under 60. Transdermal oestrogen + micronised progesterone (Utrogestan) is the safest combination based on current evidence.
4
Diagnose
Targeted Examination
Blood pressure
Mandatory before initiating HRT. Hypertension does not contraindicate transdermal HRT but must be documented and managed. Systolic >180 → control BP first.
BMI
BMI >30 increases breast cancer risk (obesity is stronger breast cancer risk factor than HRT itself). Increases VTE risk. Factor into shared decision-making — HRT risk proportionally smaller vs lifestyle risk.
Breast examination
Ensure recent mammogram (NHS Breast Screening Programme: 50–71 years, 3-yearly). Any breast mass or nipple discharge → urgent referral before HRT. Not a contraindication to HRT if current mammogram normal.
Pelvic examination
Indicated if urogenital symptoms, PMB, or IUS fitting planned. Check for atrophic vaginitis (pale, dry, friable mucosa), pelvic floor, uterine size.
Thyroid
Thyroid dysfunction mimics menopausal symptoms closely (fatigue, palpitations, mood change, irregular periods). Check clinically — TFTs if any clinical features.
Cardiovascular exam
Listen for murmurs, check for oedema. Document for baseline — HRT does not worsen established heart failure but use transdermal route.
Thyroid dysfunction — particularly hypothyroidism — is common in perimenopausal women and presents identically to menopause (fatigue, weight gain, mood changes, menstrual irregularity). Prescribing HRT for undiagnosed hypothyroidism is a significant clinical error that delays appropriate treatment. BP documentation is essential as a baseline — HRT can affect BP (particularly oral oestrogen via hepatic renin-angiotensin stimulation). Breast examination builds rapport and ensures mammographic screening is up to date.
5
Diagnose
Investigations — Targeted, not routine
TFTs
TSH — if any clinical suspicion of thyroid dysfunction. Hypothyroidism highly prevalent in same demographic. Do not attribute fatigue/weight gain to menopause without TSH.
FSH / LH / Oestradiol
NOT needed for menopause diagnosis >45 years (NICE NG23). FSH >40 IU/L × 2 on 4-week interval confirms POI in women <40. Hormone levels fluctuate — single measurement unreliable.
FBC + ferritin
Heavy perimenopausal periods → iron deficiency anaemia. Check before attributing fatigue/palpitations solely to menopause.
Lipid profile
Menopause increases LDL, decreases HDL. Check cardiovascular risk (QRISK3). Useful for shared decision-making regarding cardiovascular benefit of HRT in high-risk women.
DEXA scan
Bone density scan — indicated for POI, early menopause (<45), prolonged amenorrhoea, prior fragility fracture, or stopping HRT after long use. Not routine for women starting standard HRT.
Pelvic USS
If PMB (2WW mandatory). If fibroids suspected. Not routine before HRT initiation in asymptomatic women with regular screening history.
Do NOT order
Routine mammography before HRT (use NHS screening programme). Routine coagulation screen (no evidence changes management). Routine bone density before HRT in standard peri/menopausal women.
NICE NG23 specifies that FSH testing should not be used to diagnose perimenopause or menopause in women over 45 with typical symptoms. This is to prevent both false reassurance (normal FSH in perimenopause) and unnecessary treatment delays. QRISK3 is superior to older QRISK2 for cardiovascular risk assessment in menopausal women — it includes systemic lupus erythematosus, severe mental illness, and atrial fibrillation as risk factors relevant to this age group. DEXA is indicated in POI — these women have accelerated bone loss and monitoring response to HRT guides dose optimisation.
6
Refer
Referral Criteria
2WW Gynaecology
Postmenopausal bleeding — must exclude endometrial cancer before HRT. Persistent IMB/PCB in perimenopausal women >45 years. NICE NG12: post-menopausal bleeding 55+ → 2WW gynaecology; PMB <55 → consider a suspected gynaecological cancer referral.
Urgent Breast Clinic
New breast mass, skin tethering, nipple discharge (especially blood-stained), axillary lymphadenopathy. → Do not start HRT until assessment complete.
Specialist Menopause Clinic
POI (<40 years). Early menopause (<45). HRT failure after adequate trial. Complex medical history (multiple risk factors, oncology). Women with breast cancer requesting HRT.
Endocrinology
POI with autoimmune features (thyroid, adrenal, diabetes). Surgical menopause with complex co-morbidities. Testosterone prescribing (specialist-initiated in most areas).
Haematology
Known thrombophilia + requesting HRT. Personal or strong family VTE history. Antiphospholipid syndrome.
GP manages
Standard perimenopause / menopause >45 years with typical symptoms. No contraindications identified. Initiation and ongoing management of standard HRT regimens.
GP-led menopause management is appropriate and encouraged by NICE NG23 for the majority of women — over-referring creates unnecessary delays and access barriers. However, POI requires specialist input because of diagnostic complexity, psychological impact, and need for fertility counselling, higher-dose HRT, and DEXA monitoring. Women with VTE history can use transdermal HRT safely — haematology input is only needed if thrombophilia is confirmed or high-risk, not for all women with a VTE history.
Patches: Evorel 25/50/75/100 µg twice weekly. Gel: Oestrogel (1–2 pumps OD) or Sandrena sachets. No increased VTE or stroke risk. Preferred in all.
If transdermal not tolerated
Oral Oestradiol
Estradiol 1mg or 2mg OD (Elleste Solo, Zumenon). Increased VTE and stroke risk vs transdermal. Avoid in VTE risk factors, hypertension, migraine, BMI >30.
Urogenital symptoms only
Topical Vaginal Oestrogen
Vagifem 10mcg pessary OD ×2/52 then twice weekly. Or Ovestin cream. Negligible systemic absorption. No progestogen needed. Long-term use safe.
Progestogen — mandatory for women with uterus:
Safest option
Micronised progesterone (Utrogestan 100mg) OD continuously (if atrophic/postmenopause) or 200mg OD day 1–14 each month (if cyclical). Derived from plant sterols — lowest breast cancer signal. Sleep-promoting.
LNG-IUS
Mirena 52mg IUS — NICE-recommended progestogen delivery for HRT. Provides endometrial protection + contraception. Lasts 5 years (8 years off-label). Ideal for perimenopausal women needing both.
Synthetic progestogens
Norethisterone, medroxyprogesterone — higher breast cancer risk signal. Use if micronised progesterone/Mirena not tolerated or available. Norethisterone 5mg OD or medroxyprogesterone 10mg OD.
Tibolone (Livial 2.5mg OD) — a synthetic steroid with combined oestrogenic, progestogenic and weak androgenic activity. Postmenopausal (>12 months amenorrhoea) only; one tablet, no separate progestogen needed. May help low libido. Avoid in breast cancer history and >60 (stroke risk).
Testosterone
Intrinsa or Testogel (off-label): low-dose for hypoactive sexual desire disorder (HSDD) + menopause. Specialist-initiated in most areas. NICE supports use for HSDD if other treatments failed.
Dose titration
Start low (Evorel 25 patch, Oestrogel 1 pump). Increase after 3 months if symptoms persist. Most women need 50µg patch or equivalent. Don't over-restrict dose — inadequate dose = inadequate symptom control.
The E3N cohort study (France, n=80,000) demonstrated that transdermal oestrogen + micronised progesterone carries no increased VTE risk and the lowest breast cancer risk of any combined HRT regimen. Oral oestrogen undergoes hepatic first-pass metabolism stimulating production of clotting factors and renin — mechanistically explaining the increased VTE and hypertensive risk. The LNG-IUS as progestogen delivery is evidence-based (NICE NG23) and practically advantageous — it eliminates the need for synthetic systemic progestogen while providing contraception. Sequential vs continuous regimen selection is important — switching perimenopausal women to continuous-combined prematurely causes unscheduled bleeding and poor adherence.
Exercise — vasomotor symptoms Aerobic exercise (150 min/week moderate intensity) reduces hot flush severity by 30–50%. Mechanism: serotonin/noradrenaline pathway. Also improves mood, sleep, and bone density.
Strength training Progressive resistance training 2–3×/week — protects against menopausal muscle and bone loss. Maintains BMD equivalent to some HRT doses. Essential recommendation for all menopausal women.
Weight management Adipose tissue converts androgens to oestrone — more hot flushes in obese women paradoxically (due to oestrogen receptor downregulation). Even 5% weight loss reduces vasomotor symptom frequency.
Sleep hygiene Night sweats disrupt sleep → fatigue → mood symptoms. Cool bedroom (16–18°C), cotton nightwear, bedroom fan. Address sleep issues directly; HRT improves sleep in 60–80% within 4 weeks.
Phytoestrogens Soy isoflavones: modest evidence for mild vasomotor symptoms reduction (RCTs: 20–40% reduction). Not suitable as HRT replacement for severe symptoms. Avoid in oestrogen-sensitive cancers.
Alcohol and caffeine reduction Both are vasomotor triggers. Alcohol also disrupts sleep architecture and increases breast cancer risk. Advise ≤14 units/week. Reduce coffee if hot flushes worsen after ingestion.
CBT for menopause NICE-recommended: Mindfulness-Based Cognitive Therapy (MBCT) reduces psychological symptoms of menopause significantly. Refer to self-help resources or IAPT where HRT declined or contraindicated.
Vaginal health Regular sexual activity (including masturbation) maintains vaginal blood flow and epithelial health. Vaginal moisturisers (Replens 3×/week) + lubricants during intercourse for non-hormonal management of GSM.
Exercise is a disease-modifying intervention in menopause — it reduces osteoporosis risk (DEXA evidence: resistance training maintains BMD), reduces cardiovascular risk, and improves mood through serotonin pathways. CBT for menopausal symptoms was studied in the MENOS 1 and 2 RCTs — both showed significant reduction in how much hot flushes bother women (even if not reducing frequency). NICE NG23 recommends CBT alongside HRT or as an alternative when HRT is contraindicated. Lifestyle modifications are not a substitute for HRT in severe symptoms but substantially enhance outcomes and reduce required HRT dose.
9
Safety
Follow-Up, Monitoring & Safety-Netting
6–12 weeks
First review: symptom response (use MRS/Greene Scale), side effects (breast tenderness, bloating, breakthrough bleeding), BP recheck, patch tolerance / site reactions
3 months
Assess symptom control — if inadequate, titrate oestrogen dose upward. Check for unscheduled bleeding (investigate if on continuous combined HRT — refer if >6 months use + bleeding). Review progestogen tolerability.
Annual
Risk-benefit review. Update medical history (new diagnoses, family history). BP check. Ensure mammography screening up to date. Document continued discussion of risks and benefits. Reassess ongoing need.
HRT duration
NICE: no arbitrary time limit on HRT duration. Benefits vs risks must be re-evaluated annually. Most women use 2–5 years; some women benefit from lifelong use (especially POI, osteoporosis, severe symptoms). Do not force stopping at 5 years without clinical reason.
Stopping HRT
Taper rather than abrupt cessation to avoid rebound symptom surge. Reduce dose by 50% for 3 months before stopping. Some women may never tolerate complete cessation — discuss.
999 safety-net
Signs of VTE: unilateral leg pain + swelling. Acute chest pain + breathlessness. Stroke symptoms (FAST): facial droop, arm weakness, speech difficulty → STOP HRT + 999.
Same-day safety-net
New unexpected vaginal bleeding on HRT. New breast lump. Severe unexplained headache. Severe unilateral abdominal/pelvic pain.
The arbitrary "5-year rule" for HRT duration is not evidence-based and has no support in NICE NG23 or BMS guidelines — it stems from misinterpretation of WHI data. Annual review and documented shared decision-making is the appropriate approach, allowing women to make informed choices. Unscheduled bleeding after 6 months of continuous-combined HRT is clinically significant (5% risk of endometrial pathology) and requires investigation — it should not be attributed to "HRT side effects" without pelvic USS and possible biopsy. Stopping HRT abruptly is associated with symptom rebound; tapering is better tolerated and more likely to lead to successful discontinuation when appropriate.
Educational use only. Pathway based on: NICE NG23 (Menopause, 2015 updated 2019), British Menopause Society Guidelines 2020, MHRA Drug Safety Update Menopause 2020, FSRH Menopause and Contraception 2023, Newson Health Research, E3N Cohort Study (Fournier 2008), RCOG GTG Premature Ovarian Insufficiency. Always adapt to individual patient context.